 |
|
The Impact of Female Hormone Usage on the Lipid ProfileThe Framingham Offspring Study
Sonya M. Vaziri, MD, MPH;
Jane C. Evans, MPH;
Martin G. Larson, ScD;
Peter W. F. Wilson, MD
Arch Intern Med. 1993;153(19):2200-2206.
Abstract
| |
Background
Exogenous female hormone use appears to affect cardiovascular disease risk in both premenopausal and postmenopausal women. The purpose of this study was to evaluate the impact of exogenous female hormone usage on the lipid profile among premenopausal and postmenopausal women.
Methods
One thousand nine hundred thirty female participants of the Framingham Offspring study comprised the study population. Of the 992 premenopausal subjects, 57 were current oral contraceptive users; among the 938 postmenopausal subjects, 80 were current hormone users. The influence of hormone use on lipid and lipoprotein levels was determined using multivariable linear regression models that adjusted for age, body mass index, smoking, alcohol intake, β-blocker, and diuretic therapy. Adjusted least-squares means were calculated for each lipid and lipoprotein according to female hormone usage and menopausal status.
Results
In the premenopausal analysis, pooled oral contraceptive use was significantly related to increased levels of total cholesterol, triglycerides, high-density lipoprotein cholesterol and apolipoprotein A-I. Increased estrogen content was inversely associated with low-density lipoprotein cholesterol, and apolipoprotein B levels, while increased progestin content was inversely related to high-density lipoprotein cholesterol and apolipoprotein A-I levels. Among postmenopausal women, use of premarin only was significantly associated with increased high-density lipoprotein cholesterol and apolipoprotein A-I levels. Combination use of premarin and provera was significantly associated with increased apolipoprotein A-I levels; less powerful but still significant associations with increased high-density lipoprotein cholesterol and decreased low-density lipoprotein cholesterol were also observed.
Conclusion
In this cross-sectional analysis, oral contraceptive use is associated with both favorable and unfavorable lipid alterations with respect to atherogenic risk. Among postmenopausal women, hormone replacement therapy (both premarin only and combined premarin and provera) appears to be associated with favorable effects on the lipid profile.
(Arch Intern Med. 1993;153:2200-2206)
Author Affiliations
From the Framingham (Mass) Heart Study (Drs Vaziri, Evans, Larson, and Wilson) and the National Heart, Lung, and Blood Institute, Bethesda, Md (Drs Larson and Wilson).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
A More Atherogenic Serum Lipoprotein Profile Is Present in Women with Polycystic Ovary Syndrome: A Case-Control Study
Valkenburg et al.
J. Clin. Endocrinol. Metab. 2008;93:470-476.
ABSTRACT
| FULL TEXT
Endogenous Postmenopausal Hormones and Serum Lipids: The Atherosclerosis Risk in Communities Study
Mudali et al.
J. Clin. Endocrinol. Metab. 2005;90:1202-1209.
ABSTRACT
| FULL TEXT
Endogenous Postmenopausal Hormones and Carotid Atherosclerosis: A Case-Control Study of the Atherosclerosis Risk in Communities Cohort
Golden et al.
Am J Epidemiol 2002;155:437-445.
ABSTRACT
| FULL TEXT
The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease
Sbarouni et al.
J Am Coll Cardiol 1998;32:1244-1250.
ABSTRACT
| FULL TEXT
Exercise and Cardiovascular Disease : A New Perspective
Shern-Brewer et al.
Arterioscler. Thromb. Vasc. Bio. 1998;18:1181-1187.
ABSTRACT
| FULL TEXT
Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy
BMJ 1996;312:473-478.
ABSTRACT
| FULL TEXT
Association Between Increased Estrogen Status and Increased Fibrinolytic Potential in the Framingham Offspring Study
Gebara et al.
Circulation 1995;91:1952-1958.
ABSTRACT
| FULL TEXT
PEPI in Perspective: Good Answers Spawn Pressing Questions
Healy
JAMA 1995;273:240-241.
ABSTRACT
Hormonal Treatment of Postmenopausal Women
Bittner and Belchetz
NEJM 1994;331:550-550.
FULL TEXT
Tubal Ligation, Hysterectomy, and Risk of Ovarian Cancer
Whitmore
JAMA 1994;271:1236-1236.
ABSTRACT
Hormonal Therapy and Serum Lipids
Journal Watch Dermatology 1993;1993:13-13.
FULL TEXT
HORMONAL THERAPY AND SERUM LIPIDS
JWatch General 1993;1993:2-2.
FULL TEXT
Contributions of total and regional fat mass to risk for cardiovascular disease in older women
Van Pelt et al.
Am. J. Physiol. Endocrinol. Metab. 2002;282:E1023-E1028.
ABSTRACT
| FULL TEXT
|
